KRAS and pancreatic intraductal papillary-mucinous neoplasm: Although GNAS, KRAS, and TP53 mutations are helpful in identifying patients with IPMN, they occur early in the development of IPMNs and cannot be used to identify those individuals with high-grade dysplasia or invasive disease.